Safety and feasibility of establishing an adjuvant hepatic artery infusion program

Lauren M. Janczewski, Rachel H. Joung, Amir A. Borhani, Robert J. Lewandowski, Yury S. Velichko, Mary F. Mulcahy, Devalingam Mahalingam, Jennifer Law, Caitlin Bowman, Rajesh N. Keswani, Vitaliy Y. Poylin, David J. Bentrem, Ryan P. Merkow*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Hepatic artery infusion (HAI) is less frequently used in the adjuvant setting for resectable colorectal liver metastasis (CRLM) due to concerns regarding toxicity. Our objective was to evaluate the safety and feasibility of establishing an adjuvant HAI program. Methods: Patients who underwent HAI pump placement between January 2019 and February 2023 for CRLM were identified. Complications and HAI delivery were compared between patients who received HAI in the unresectable and adjuvant settings. Results: Of 51 patients, 23 received HAI for unresectable CRLM and 28 in the adjuvant setting. Patients with unresectable CRLM more commonly had bilobar disease (n = 23/23 vs n = 18/28, p < 0.01) and more preoperative liver metastases (median 10 [IQR 6–15] vs 4 [IQR 3–7], p < 0.01). Biliary sclerosis was the most common complication (n = 2/23 vs n = 4/28); however, there were no differences in postoperative or HAI-specific complications. In the most recent two years, 0 patients in the unresectable group vs 2 patients in the adjuvant group developed biliary sclerosis. All patients were initiated on HAI with no difference in treatment times or dose reductions. Conclusion: Adjuvant HAI is safe and feasible for patients with resectable CRLM. HAI programs can carefully consider including patients with resectable CRLM if managed by an experienced multidisciplinary team with quality assurance controls in place.

Original languageEnglish (US)
Pages (from-to)656-663
Number of pages8
JournalHPB
Volume26
Issue number5
DOIs
StatePublished - May 2024

Funding

Lauren M Janczewski is supported by a grant by the National Cancer Institute ( T32CA247801 ).

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Safety and feasibility of establishing an adjuvant hepatic artery infusion program'. Together they form a unique fingerprint.

Cite this